INTRODUCTION: Procalcitonin (PCT) and C-reactive protein (CRP) are established markers of infection in the general population. In contrast, several studies reported falsely increased PCT levels in patients receiving T-cell antibodies. We evaluated the validity of these markers in patients scheduled for hemopoietic stem cell transplantation receiving anti-thymocyte globulin (ATG) during conditioning. We also assessed renal and liver functions and their relationship to PCT and CRP changes. METHODS: Twenty-six patients without clinical signs of infection were prospectively studied. ATG was administered in up to three doses over the course of 5 days. PCT, CRP, white blood cell (WBC) count, urea, creatinine, glomerular filtration rate, bilirubin, alanin amino-transferase (ALT), and gamma-glutamyl transferase (GGT) were assessed daily during ATG administration. Pharyngeal, nose, and rectal swabs and urine samples were cultured twice weekly. Blood cultures were obtained if clinical symptoms of infection were present. RESULTS: Baseline (BL) levels of both PCT and CRP before ATG administration were normal. WBC count decreased after ATG administration (P = 0.005). One day after ATG administration, both PCT and CRP levels increased significantly, returning to BL levels on day 4. Microbiological results were clinically unremarkable. There was no interrelationship between PCT levels and BL markers of renal or liver functions (P > 0.05 for all comparisons). Bilirubin and GGT were increased on days 2 to 5 and ALT was increased on day 3 (P < 0.05 versus BL). No difference in renal functions was observed. Three patients developed bacterial infection on days 7 to 11 with different dynamics of PCT and CRP. There was no association between the number of ATG doses and PCT levels or between the risk of developing infection and previous PCT levels. CONCLUSIONS: ATG triggered a marked early surge in PCT and CRP followed by a steady decrease over the course of 3 days. The dynamics of both PCT and CRP were similar and were not associated with infection. PCT levels were independent of renal and liver functions and were not predictive of further infectious complications. A direct effect of ATG on T lymphocytes could be the underlying mechanism. Hepatotoxic effect could be a contributing factor. Neither PCT nor CRP is a useful marker that can identify infection in patients receiving ATG.

Institute of Clinical Biochemistry and Laboratory Diagnostics General Teaching Hospital U nemocnice 2 CZ 128 08 Prague 2 Czech Republic

Crit Care. 2009;13(3):149. doi: 10.1186/cc7799. PubMed

Zobrazit více v PubMed

Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 2004;8:R234–242. doi: 10.1186/cc2877. PubMed DOI PMC

Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P, Lubos D, Aoun M, Athanassiou K, Bouza E, Devigili E, Krcmery V, Menichetti F, Panaretou E, Papageorgiou E, Plachouras D. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 2004;10:628–633. doi: 10.1111/j.1469-0691.2004.00883.x. PubMed DOI

Robinson JO, Calandra T, Marchetti O. [Utility of procalcitonin for the diagnosis and the follow-up of infections in febrile neutropenic patients] Rev Med Suisse. 2005;1:878–882. PubMed

Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muñoz A, López-Martín A, Durán I, Robles L, Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100:2462–2469. doi: 10.1002/cncr.20275. PubMed DOI

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874. PubMed

Sabat R, Hoflich C, Docke WD, Oppert M, Kern F, Windrich B, Rosenberger C, Kaden J, Volk HD, Reinke P. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med. 2001;27:987–991. doi: 10.1007/s001340100949. PubMed DOI

Zazula R, Prucha M, Tyll T, Kieslichova E. Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin. Crit Care. 2007;11:R131. doi: 10.1186/cc6202. PubMed DOI PMC

Dornbusch HJ, Strenger V, Kerbl R, Lackner H, Schwinger W, Sovinz P, Urban C. Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis. Bone Marrow Transplant. 2003;32:941–945. doi: 10.1038/sj.bmt.1704265. PubMed DOI

Pihusch M, Pihusch R, Fraunberger P, Pihusch V, Andreesen R, Kolb HJ, Holler E. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol. 2006;76:93–101. doi: 10.1111/j.0902-4441.2005.00568.x. PubMed DOI

Dornbusch HJ, Strenger V, Sovinz P, Lackner H, Schwinger W, Kerbl R, Urban C. Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Support Care Cancer. 2008;16:1035–1040. doi: 10.1007/s00520-007-0381-1. PubMed DOI

Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, Jager L, Reinhart K. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro . J Lab Clin Med. 1999;134:49–55. doi: 10.1016/S0022-2143(99)90053-7. PubMed DOI

Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, Limburg PC, ten Duis HJ, Moshage H, Hoekstra HJ, Bijzet J, Zwaveling JH. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28:458–461. doi: 10.1097/00003246-200002000-00028. PubMed DOI

Kretzschmar M, Kruger A, Schirrmeister W. Procalcitonin following elective partial liver resection – origin from the liver? Acta Anaesthesiol Scand. 2001;45:1162–1167. doi: 10.1034/j.1399-6576.2001.450918.x. PubMed DOI

Snider RH, Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med. 1997;45:552–560. PubMed

Russwurm S, Stonans I, Stonane E, Wiederhold M, Luber A, Zipfel PF, Deigner HP, Reinhart K. Procalcitonin and CGRP-1 mrna expression in various human tissues. Shock. 2001;16:109–112. doi: 10.1097/00024382-200116020-00004. PubMed DOI

Kuse ER, Jaeger K. Procalcitonin increase after anti-CD3 monoclonal antibody therapy does not indicate infectious disease. Transpl Int. 2001;14:55. doi: 10.1111/j.1432-2277.2001.tb00011.x. PubMed DOI

Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998;24:888–889. doi: 10.1007/s001340050683. PubMed DOI

Sponholz C, Sakr Y, Reinhart K, Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care. 2006;10:R145. doi: 10.1186/cc5067. PubMed DOI PMC

Nylen ES, Al Arifi A, Becker KL, Snider RH, Jr, Alzeer A. Effect of classic heatstroke on serum procalcitonin. Crit Care Med. 1997;25:1362–1365. doi: 10.1097/00003246-199708000-00024. PubMed DOI

Assumma M, Signore F, Pacifico L, Rossi N, Osborn JF, Chiesa C. Serum procalcitonin concentrations in term delivering mothers and their healthy offspring: a longitudinal study. Clin Chem. 2000;46:1583–1587. PubMed

Lorton F, Veinberg F, Ielsch D, Deschenes G, Bensman A, Ulinski T. Procalcitonin serum levels in children undergoing chronic haemodialysis. Pediatr Nephrol. 2007;22:430–435. doi: 10.1007/s00467-006-0304-2. PubMed DOI

Steinbach G, Bolke E, Grunert A, Storck M, Orth K. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr. 2004;116:849–853. doi: 10.1007/s00508-004-0279-6. PubMed DOI

Bolko P, Manuszewska-Jopek E, Michalek K, Wasko R, Jaskula M, Sowinski J. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz) 2003;51:415–419. PubMed

Ittner L, Born W, Rau B, Steinbach G, Fischer JA. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol. 2002;147:727–731. doi: 10.1530/eje.0.1470727. PubMed DOI

Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49:1752–1761. doi: 10.1080/10428190802258956. PubMed DOI

Changes in Sepsis Biomarkers after Immunosuppressant Administration in Transplant Patients